TY - JOUR
T1 - Counting the carbon cost of heparin
T2 - an evolving tragedy of the commons?
AU - Fan, Bingwen Eugene
AU - Favaloro, Emmanuel J
PY - 2022/7
Y1 - 2022/7
N2 - Heparin, which is listed in WHO's Model List of Essential Medicines, 1 was discovered in 1916 and has been used as an anticoagulant since 1935, possessing potentiating effects on antithrombin. The global demand for heparin is rising, with the global heparin pharmaceutical market projected to grow from US$9·38 billion in 2021 to US$12·06 billion in 2028, and there is a possibility that demand might outstrip supply. 2 In addition to increased usage for treatment of rising cardiovascular disease and thrombosis cases in ageing populations, the demand for heparin has been exacerbated by its use during the COVID-19 pandemic for thromboprophylaxis and treatment of COVID-19-associated thromboembolic disease.
AB - Heparin, which is listed in WHO's Model List of Essential Medicines, 1 was discovered in 1916 and has been used as an anticoagulant since 1935, possessing potentiating effects on antithrombin. The global demand for heparin is rising, with the global heparin pharmaceutical market projected to grow from US$9·38 billion in 2021 to US$12·06 billion in 2028, and there is a possibility that demand might outstrip supply. 2 In addition to increased usage for treatment of rising cardiovascular disease and thrombosis cases in ageing populations, the demand for heparin has been exacerbated by its use during the COVID-19 pandemic for thromboprophylaxis and treatment of COVID-19-associated thromboembolic disease.
KW - Carbon
KW - Heparin/therapeutic use
KW - Humans
UR - http://www.scopus.com/inward/record.url?scp=85132878579&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85132878579&partnerID=8YFLogxK
U2 - 10.1016/S2352-3026(22)00171-5
DO - 10.1016/S2352-3026(22)00171-5
M3 - Comment/debate
C2 - 35688174
SN - 2352-3026
VL - 9
SP - e469-e471
JO - The Lancet Haematology
JF - The Lancet Haematology
IS - 7
ER -